Clomid vs Ovidrel: What to Do When One Fails

What Clomid and Ovidrel Actually Do (and Why They Are Not Interchangeable)

These two drugs are not competitors doing the same job. They act at completely different points in the ovulation cycle, and mixing them up is the most common source of confusion in fertility forums.

Clomid: The Pituitary Messenger

Clomiphene citrate works by blocking estrogen receptors in your hypothalamus. Your hypothalamus sees low estrogen and sends more gonadotropin-releasing hormone (GnRH) to your pituitary, which then releases more FSH. That FSH pushes a follicle, or sometimes several follicles, to grow. Clomiphene does nothing to trigger the LH surge that actually releases the egg.

A standard starting dose is 50 mg/day for five days, typically on cycle days 3 through 7. If there is no response, the dose steps up by 50 mg per cycle to a ceiling of 150 mg/day. Most clinicians do not extend clomiphene trials beyond six ovulatory cycles.

Ovidrel: The Trigger

Choriogonadotropin alfa (Ovidrel) is recombinant human chorionic gonadotropin. It mimics the natural LH surge and tells a mature follicle to complete its final maturation and rupture, releasing the egg. A single injection of 250 mcg subcutaneously is the standard trigger dose, given when the lead follicle reaches approximately 18-20 mm on transvaginal ultrasound.

Ovidrel does nothing if your follicles are not ready. It is a finisher, not a starter.

Why They Are Often Used Together

In a monitored timed intercourse or IUI cycle, the standard sequence is: Clomid grows the follicle, serial ultrasounds confirm follicular maturity, then Ovidrel triggers ovulation. Intercourse or insemination is timed 24-36 hours after the injection. Used this way, the two drugs are additive, not redundant.

When Clomid Fails: What That Actually Means

"Clomid failed" covers three very different clinical situations, each requiring a different response.

Failure Type 1: No Ovulation (Clomiphene Resistance)

You took Clomid, had monitored cycles, and never produced a follicle larger than 14 mm or never got a positive ovulation predictor kit reading confirmed by progesterone. This is true clomiphene resistance. It affects up to 25% of women with PCOS who receive the maximum dose of 150 mg. Common drivers include BMI above 35, severe insulin resistance, very high baseline LH, and elevated androgen levels.

In this situation, adding Ovidrel is useless. There is no mature follicle to trigger.

Failure Type 2: Ovulation Without Pregnancy (Clomiphene Success, Conception Failure)

Your follicle grew, your progesterone confirmed ovulation, but you did not conceive over three to six cycles. Here Clomid is working mechanically but something else is limiting conception. Possible factors include:

• Anti-estrogenic effect on the endometrium (thin lining, <7 mm) caused by clomiphene's prolonged receptor blockade
• Hostile cervical mucus from the same anti-estrogenic effect
• Timing of intercourse missing the actual ovulation window
• An undetected tubal or sperm factor

Adding Ovidrel is a rational step here because it tightens the timing window. When you know egg release will occur 36-40 hours after injection, timed intercourse or IUI becomes far more precise. The Ovidrel is not solving a clomiphene problem; it is solving a timing problem.

Failure Type 3: Ovulation, Adequate Lining, Confirmed Timing, Still No Pregnancy

After four to six cycles with documented ovulation, good lining, timed intercourse, and a normal semen analysis, the conversation shifts away from oral ovulation induction entirely. ASRM practice guidelines recommend reassessing the full workup at this point and discussing either letrozole (which avoids clomiphene's anti-estrogenic endometrial effects) or moving to injectable gonadotropins with IUI.

When Ovidrel Fails: What That Actually Means

Ovidrel "failure" is less common than Clomid failure but also has distinct subtypes.

The Follicle Was Not Ready

The most frequent cause: the trigger was given before the lead follicle reached 18 mm. A follicle at 14-15 mm is not yet capable of releasing a mature, fertilizable egg even with an hCG push. The solution is better monitoring, not a different drug.

Luteinized Unruptured Follicle (LUF) Syndrome

Some women show the hormonal signs of ovulation, including a progesterone rise, but the follicle wall never physically ruptures. The egg is trapped. Transvaginal ultrasound can confirm this by showing a persistent, non-collapsing follicle after the expected ovulation window. Switching from Ovidrel to a GnRH agonist trigger (leuprolide acetate) is sometimes used in this setting, though LUF syndrome data in natural-cycle and low-stimulation protocols remains limited.

Ovidrel in the Absence of Clomiphene or Gonadotropin Priming

Using Ovidrel without any follicular development phase is ineffective by design. Occasional patients request a trigger shot without prior stimulation. A small follicle cannot be rushed to maturity by hCG alone.

The PCOS-Specific Picture

PCOS is the most common reason women are prescribed Clomid in the first place, and the evidence base here is the most detailed. The landmark NEJM PPCOS II trial randomized 750 women with PCOS to clomiphene or letrozole and found live birth rates of 27.5% for letrozole versus 19.1% for clomiphene over five cycles. That gap matters because it means clomiphene, not just "oral ovulation induction," is a suboptimal first choice in PCOS.

When clomiphene is used in PCOS and fails to trigger ovulation, the mechanistic problem is usually the hyperandrogenic, high-LH hormonal environment that blunts the hypothalamus-pituitary axis response. Adding a metformin co-treatment has been shown in meta-analyses to improve ovulation rates in clomiphene-resistant PCOS, though live birth data are less consistent. Inositol supplementation is popular but the evidence does not yet support it as a replacement for established treatments.

For women with PCOS who ovulate on Clomid but do not conceive, adding the Ovidrel trigger to tighten timing is a low-cost, well-tolerated next step before escalating to injectables.

Life Stage: How Your Hormonal Status Changes the Calculus

Not every woman asking about Clomid and Ovidrel is in the same hormonal chapter of her life. The drugs behave differently depending on where you are.

Reproductive Years (Ages 18-35, Regular Cycles)

This is the classic population for both drugs. Clomid works best when baseline FSH is normal (<10 IU/L) and the ovaries have adequate antral follicle counts. Ovidrel is a routine add-on for timed intercourse and IUI. Response rates are generally highest in this group.

Trying to Conceive After 35 (Diminished Ovarian Reserve Territory)

As ovarian reserve declines, baseline FSH rises. Clomiphene depends on pituitary FSH amplification, and if your pituitary is already firing hard (elevated FSH on its own), clomiphene adds little incremental drive. Women with AMH below 0.5 ng/mL or FSH above 12 IU/L are poor candidates for clomiphene as first-line treatment. Injectable gonadotropins, which bypass pituitary signaling entirely, are more appropriate. Ovidrel remains useful as a trigger in these protocols.

Perimenopause

Clomiphene has essentially no role in perimenopause for fertility purposes. Perimenopausal ovaries do not reliably respond to FSH amplification, and the erratic cycle lengths make protocol timing unreliable. Ovidrel could theoretically trigger a spontaneous dominant follicle in early perimenopause, but this is not a standard, guideline-supported protocol and should not be attempted without reproductive endocrinology oversight.

PCOS Across the Reproductive Lifespan

Women with PCOS often have a longer reproductive window than age-matched controls, but the first-line shift from clomiphene to letrozole, established by PPCOS II, applies regardless of age within the reproductive years. Ovidrel adds timing precision in both clomiphene and letrozole cycles.

Postpartum and Breastfeeding

Neither Clomid nor Ovidrel is indicated while breastfeeding. Both are used to induce ovulation for conception, and postpartum women who are breastfeeding typically have lactation-mediated anovulation that resolves naturally. Resuming ovulation-induction agents during lactation is not appropriate.

Pregnancy and Lactation Safety

Read this section before starting either drug.

Clomiphene (Clomid): Pregnancy and Lactation

Clomiphene carries an FDA Pregnancy Category X designation, meaning animal and human data show fetal risk that outweighs any possible benefit. It must be stopped before or immediately upon confirmed pregnancy. There is no indication for clomiphene use during pregnancy.

Clomiphene does transfer into breast milk in small amounts, and because its effects on the nursing infant are unknown, it should not be used during lactation.

Women with irregular cycles who may already be pregnant must have a negative pregnancy test confirmed before starting each cycle of clomiphene.

Ovidrel (Choriogonadotropin Alfa): Pregnancy and Lactation

Ovidrel is FDA Pregnancy Category X as well. Because Ovidrel itself elevates serum hCG, taking a pregnancy test within 10-14 days of the injection will likely show a false positive. Your clinician will time your blood pregnancy test to avoid this window.

Ovidrel should not be used during lactation. There are no adequate studies of transfer into human milk, and the peptide hormone structure means potential suppression of lactation is a theoretical risk.

Multiple Pregnancy Risk

Both drugs increase the chance of a multiple pregnancy compared with unassisted conception. Clomiphene multiples are mostly twins (approximately 8% twin rate, <1% higher-order multiples). Adding Ovidrel to a clomiphene cycle does not eliminate this risk and requires follicle-count monitoring before triggering. Cycles with more than two mature follicles (>17 mm) carry a meaningful multiple-pregnancy risk and may be cancelled or converted to IVF egg retrieval by your reproductive endocrinologist.

Who Is Right for Each Drug, and Who Is Not

Clomid Is a Reasonable Starting Point If:

• You have PCOS or hypothalamic anovulation with normal FSH and AMH
• You are under 38 with a normal ovarian reserve
• Your partner's semen analysis is normal or near-normal
• Your tubes are patent (confirmed by HSG or sonohysterogram)
• You are willing to do monitored cycles with ultrasound and progesterone checks

Clomid Is NOT the Right Choice If:

• Your FSH is consistently above 12 IU/L or AMH below 0.5 ng/mL
• You have documented clomiphene resistance after 150 mg for three cycles
• You have a thin endometrium on clomiphene (lining persistently <7 mm)
• Letrozole has not been tried in a PCOS patient (per ASRM guidance, letrozole is now preferred first-line)
• You are in perimenopause

Ovidrel Is Appropriate If:

• You are in a monitored cycle and the lead follicle has reached 18-20 mm
• You want tighter control over ovulation timing for IUI or timed intercourse
• Your cycle monitoring shows a slow or absent spontaneous LH surge
• Your IVF or egg-freezing protocol requires a trigger

Ovidrel Is NOT Appropriate If:

• No mature follicle is present on ultrasound at the time of trigger
• You have confirmed pregnancy
• You are breastfeeding

The Switching Decision: A Practical Sequence

When a patient asks "should I switch from Clomid to Ovidrel," the answer depends on the diagnosis. Here is the decision logic WomanRx uses, reviewed by our editorial board:

1. Confirm what failed. Did Clomid fail to produce a follicle, or did it produce a follicle but not a pregnancy?
2. If no follicle: Ovidrel will not help. Consider letrozole, metformin co-treatment (in PCOS), or injectable gonadotropins. Refer to reproductive endocrinology.
3. If follicle grew but timing was uncertain: Add Ovidrel as a trigger. This is the most common "switch" and it is really an addition, not a replacement.
4. If follicle grew, timing was confirmed, lining was adequate, and three to six cycles failed: Move past clomiphene entirely. The ASRM practice committee recommends reassessment and considers letrozole or injectable gonadotropins at this stage.
5. If PCOS is the diagnosis and letrozole has never been tried: Switch to letrozole before adding or changing triggers. The PPCOS II data support this decisively.

"The most common mistake I see is women spending six cycles on clomiphene when letrozole is clearly the better first-line agent in PCOS. The PPCOS II trial settled that question in 2014. Ovidrel is a useful add-on for timing, but it cannot fix an endometrium that clomiphene has thinned, and it certainly cannot trigger an egg that never matured," says Dr. Elena Vasquez, MD, WomanRx Editorial Board Reviewer in Reproductive Endocrinology.

Evidence Gaps: What We Do Not Know

Women deserve an honest accounting of where the evidence is thin.

Most clomiphene trials were conducted in the 1980s and 1990s, before routine transvaginal ultrasound monitoring and before AMH testing existed. Dosing norms were set without systematic endometrial lining criteria. The anti-estrogenic endometrial effect of clomiphene was recognized clinically long before prospective trials quantified its frequency.

Ovidrel's pharmacokinetics in women with PCOS (who clear hCG differently due to altered FSH receptor expression) have not been studied in large, prospective trials. The hCG trigger literature on which dosing recommendations rest was largely conducted in IVF populations, where the clinical context differs from IUI or timed intercourse cycles.

The interaction between clomiphene-thinned endometrium and Ovidrel-timed intercourse has not been studied in a randomized controlled trial. Clinicians extrapolate from IVF data and observational IUI cohorts. If you have been told your lining is consistently thin on clomiphene, ask your provider about endometrial thickness data from your specific monitored cycles before agreeing to more Ovidrel-triggered attempts.

Monitoring Requirements: What to Expect at Each Step

Unmonitored clomiphene cycles are common in primary care settings but carry avoidable risks. Monitored cycles are the standard of care in reproductive endocrinology for good reason.

What Monitoring Looks Like on a Clomiphene Cycle

• Baseline ultrasound (cycle day 2-3): Rules out ovarian cysts before starting. A cyst above 20 mm on the day of starting clomiphene may prompt cycle cancellation.
• Mid-cycle ultrasound (approximately cycle day 10-12): Measures follicle size and endometrial thickness.
• Trigger decision: If lead follicle is 18-20 mm, Ovidrel is administered. If lining is below 7 mm, some clinicians add low-dose estrogen supplementation or consider cycle cancellation.
• Luteal phase progesterone (cycle day 21 in a 28-day cycle or 7 days post-trigger): Confirms ovulation. A level above 3 ng/mL confirms ovulation; many reproductive endocrinologists prefer above 10 ng/mL for adequate luteal function.

What Monitoring Looks Like on an Ovidrel-Only Protocol

Ovidrel is never given without prior ultrasound confirmation of follicle maturity. Any protocol skipping the pre-trigger scan is not following standard practice. Ask for your follicle size measurement before you inject.

Cost and Access Considerations

Clomiphene is available as a generic and costs roughly $10-50 per cycle at most US pharmacies. Ovidrel, as a brand-name recombinant product, costs approximately $80-150 per injection without insurance coverage. Many insurance plans that cover infertility diagnostics will also cover Ovidrel as a medically necessary trigger; a prior authorization letter citing ACOG guidance on monitored ovulation induction is often sufficient.

Generic hCG products (urinary-derived hCG, such as Novarel or Pregnyl) are functionally equivalent triggers at lower cost. Ask your pharmacist or clinic whether a urinary hCG preparation is available as an alternative if Ovidrel's cost is a barrier.